Table of Content

1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Global Specialty Generics Market: Introduction

5 Why are Specialty Generics So Lucrative?

6 Global Specialty Generics Market
6.1 Market Overview
6.2 Market Performance
6.3 Impact of COVID-19
6.4 Market Breakup by Route of Administration
6.5 Market Breakup by Indication
6.6 Market Breakup by Distribution Channel
6.7 Market Breakup by Region
6.8 Market Forecast
6.9 SWOT Analysis
6.9.1 Overview
6.9.2 Strengths
6.9.3 Weaknesses
6.9.4 Opportunities
6.9.5 Threats
6.10 Value Chain Analysis
6.11 Porters Five Forces Analysis
6.11.1 Overview
6.11.2 Bargaining Power of Buyers
6.11.3 Bargaining Power of Suppliers
6.11.4 Degree of Competition
6.11.5 Threat of New Entrants
6.11.6 Threat of Substitutes
6.12 Key Market Drivers and Success Factors

7 Market Breakup by Route of Administration
7.1 Injectable
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Oral
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Others
7.3.1 Market Trends
7.3.2 Market Forecast

8 Market Breakup by Indication
8.1 Oncology
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Autoimmune Diseases
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Infectious Diseases
8.3.1 Market Trends
8.3.2 Market Forecast
8.4 Others
8.4.1 Market Trends
8.4.2 Market Forecast

9 Market Breakup by Distribution Channel
9.1 Retail Pharmacies
9.1.1 Market Trends
9.1.2 Market Forecast
9.2 Specialty Pharmacies
9.2.1 Market Trends
9.2.2 Market Forecast
9.3 Hospital Pharmacies
9.3.1 Market Trends
9.3.2 Market Forecast

10 Market Breakup by Region
10.1 North America
10.1.1 Market Overview
10.1.2 Market Performance
10.1.3 Market Breakup by Country
10.1.3.1 United States
10.1.3.1.1 Market Trends
10.1.3.1.2 Market Forecast
10.1.3.2 Canada
10.1.3.2.1 Market Trends
10.1.3.2.2 Market Forecast
10.1.4 Market Forecast
10.2 Europe
10.2.1 Market Overview
10.2.2 Market Performance
10.2.3 Market Breakup by Country
10.2.3.1 Italy
10.2.3.1.1 Market Trends
10.2.3.1.2 Market Forecast
10.2.3.2 Germany
10.2.3.2.1 Market Trends
10.2.3.2.2 Market Forecast
10.2.3.3 France
10.2.3.3.1 Market Trends
10.2.3.3.2 Market Forecast
10.2.3.4 United Kingdom
10.2.3.4.1 Market Trends
10.2.3.4.2 Market Forecast
10.2.3.5 Spain
10.2.3.5.1 Market Trends
10.2.3.5.2 Market Forecast
10.2.4 Market Forecast
10.3 Asia Pacific
10.3.1 Market Overview
10.3.2 Market Performance
10.3.3 Market Breakup by Country
10.3.3.1 Japan
10.3.3.1.1 Market Trends
10.3.3.1.2 Market Forecast
10.3.3.2 China
10.3.3.2.1 Market Trends
10.3.3.2.2 Market Forecast
10.3.3.3 India
10.3.3.3.1 Market Trends
10.3.3.3.2 Market Forecast
10.3.3.4 South Korea
10.3.3.4.1 Market Trends
10.3.3.4.2 Market Forecast
10.3.4 Market Forecast
10.4 Latin America
10.4.1 Market Overview
10.4.2 Market Performance
10.4.3 Market Breakup by Country
10.4.3.1 Brazil
10.4.3.1.1 Market Trends
10.4.3.1.2 Market Forecast
10.4.3.2 Mexico
10.4.3.2.1 Market Trends
10.4.3.2.2 Market Forecast
10.4.4 Market Forecast
10.5 Middle East and Africa
10.5.1 Market Overview
10.5.2 Market Performance
10.5.3 Market Forecast

11 Competitive Landscape
11.1 Market Structure
11.2 Key Players
11.3 Profiles of Key Players
11.3.1 Teva Pharmaceuticals Industries
11.3.2 Akorn, Inc.
11.3.3 Mylan N.V.
11.3.4 Mallinckrodt
11.3.5 Sandoz International GmbH
11.3.6 Pfizer, Inc.
11.3.7 Sun Pharmaceutical Industries Ltd.
11.3.8 Valeant Pharmaceuticals
11.3.9 Apotex Corp.
11.3.10 Endo International plc.